Catalyst Pharmaceuticals (NASDAQ:CPRX) Given “Outperform” Rating at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $29.00 price target on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Cantor Fitzgerald reiterated an overweight rating and issued a $34.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. Bank of America started coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They set a buy rating and a $23.00 target price for the company. StockNews.com raised shares of Catalyst Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, March 21st. Citigroup began coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 14th. They issued a buy rating and a $27.00 price objective for the company. Finally, TheStreet upgraded shares of Catalyst Pharmaceuticals from a c+ rating to a b rating in a research note on Tuesday, March 12th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of Buy and a consensus target price of $26.43.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $16.27 on Wednesday. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of 26.67, a price-to-earnings-growth ratio of 1.11 and a beta of 0.92. The business has a 50 day moving average price of $14.96 and a two-hundred day moving average price of $14.17. Catalyst Pharmaceuticals has a 1-year low of $11.09 and a 1-year high of $18.22.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. The company had revenue of $110.57 million for the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. Equities analysts expect that Catalyst Pharmaceuticals will post 1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its position in Catalyst Pharmaceuticals by 16.7% during the first quarter. Bank of New York Mellon Corp now owns 569,542 shares of the biopharmaceutical company’s stock worth $4,722,000 after buying an additional 81,325 shares in the last quarter. MetLife Investment Management LLC increased its position in shares of Catalyst Pharmaceuticals by 39.7% during the first quarter. MetLife Investment Management LLC now owns 49,347 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 14,017 shares during the period. APG Asset Management N.V. acquired a new position in shares of Catalyst Pharmaceuticals in the first quarter valued at $1,093,000. Dimensional Fund Advisors LP lifted its position in Catalyst Pharmaceuticals by 12.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,145,254 shares of the biopharmaceutical company’s stock worth $17,784,000 after purchasing an additional 241,686 shares during the period. Finally, Sei Investments Co. boosted its stake in Catalyst Pharmaceuticals by 70.1% during the first quarter. Sei Investments Co. now owns 295,714 shares of the biopharmaceutical company’s stock worth $2,445,000 after buying an additional 121,870 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.